Last reviewed · How we verify
pexelizumab in conjunction with CABG
Pexelizumab is a monoclonal antibody that inhibits the complement component 5 (C5) to reduce inflammation.
Pexelizumab is a monoclonal antibody that inhibits the complement component 5 (C5) to reduce inflammation. Used for Cardiac surgery for reduction of mortality and morbidity.
At a glance
| Generic name | pexelizumab in conjunction with CABG |
|---|---|
| Sponsor | Alexion Pharmaceuticals, Inc. |
| Drug class | Monoclonal antibody |
| Target | Complement component 5 (C5) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting C5, pexelizumab prevents the formation of the membrane attack complex, which is involved in the inflammatory response. This action is thought to reduce tissue damage and improve outcomes in patients undergoing cardiac surgery. Pexelizumab has been investigated for its potential to reduce the risk of acute kidney injury and other complications associated with cardiac surgery.
Approved indications
- Cardiac surgery for reduction of mortality and morbidity
Common side effects
- Thrombocytopenia
- Anemia
- Neutropenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: